News

PMLive6h
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...
Seeking Alpha2d
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...
Applied Clinical Trials Online2d
QUASAR LTE Trial Shows Tremfya Produces Sustained Clinical, Endoscopic Remission Through 92 Weeks in Ulcerative Colitis
New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...
Pharmabiz1d
Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis
Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...
BlackDoctor.org7d
Hope in Every Dose: New Treatments for Ulcerative Colitis in 2025
Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...
Seeking Alpha1mon
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with ...
TREMFYA ® demonstrated clinically meaningful ... Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL ...
Investing2d
TREMFYA shows promise in ulcerative colitis study
SAN DIEGO - Johnson & Johnson (NYSE: JNJ) announced today that its Phase 3 ASTRO study of TREMFYA® (guselkumab) demonstrated significant clinical remission and endoscopic improvement in adults ...
Hosted on MSN8d
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...
Mena FN1mon
TREMFYA® (Guselkumab) Receives Positive CHMP Opinion For Treatment Of Patients With Moderately To Severely Active Crohn’S Disease
Accessed March 2025. 4 Johnson & Johnson Innovative Medicine. TREMFYA ® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative ...
Johnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis
Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...
Morningstar2d
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to ...